GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Talphera Inc (NAS:TLPH) » Definitions » Pretax Margin %

Talphera (Talphera) Pretax Margin % : -1,604.98% (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Talphera Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Talphera's Pre-Tax Income for the three months ended in Dec. 2023 was $-4.51 Mil. Talphera's Revenue for the three months ended in Dec. 2023 was $0.28 Mil. Therefore, Talphera's pretax margin for the quarter that ended in Dec. 2023 was -1,604.98%.

The historical rank and industry rank for Talphera's Pretax Margin % or its related term are showing as below:

TLPH' s Pretax Margin % Range Over the Past 10 Years
Min: -2325.78   Med: -745.48   Max: -122.72
Current: -1580.18


TLPH's Pretax Margin % is ranked worse than
96.28% of 1022 companies
in the Drug Manufacturers industry
Industry Median: 4.555 vs TLPH: -1580.18

Talphera Pretax Margin % Historical Data

The historical data trend for Talphera's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Talphera Pretax Margin % Chart

Talphera Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,325.78 -745.48 -1,245.35 - -1,580.18

Talphera Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -1,749.01 -1,210.26 -1,604.98

Competitive Comparison of Talphera's Pretax Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Talphera's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Talphera's Pretax Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Talphera's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Talphera's Pretax Margin % falls into.



Talphera Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Talphera's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-10.287/0.651
=-1,580.18 %

Talphera's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-4.51/0.281
=-1,604.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Talphera  (NAS:TLPH) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Talphera Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Talphera's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Talphera (Talphera) Business Description

Traded in Other Exchanges
Address
25821 Industrial Boulevard, Suite 400, Hayward, CA, USA, 94545
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Its product portfolio includes Niyad that is a lyophilized formulation of nafamostat. It is also developing two pre-filled syringes, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe.
Executives
Vincent J. Angotti director, officer: Chief Executive Officer C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Pamela P Palmer director, officer: Chief Medical Officer C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Jill Marie Broadfoot director 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Marina Bozilenko director C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Adrian Adams director C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19355
Mark G Edwards director ALLOS THERAPEUTICS, INC., 11080 CIRCLEPOINT ROAD, SUITE 200, WESTMINSTER CO 80020
Raffi Asadorian officer: Chief Financial Officer C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Lawrence G Hamel officer: Chief Development Officer C/O ACELRX PHARMACEUTICALS INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Badri N Dasu officer: Chief Engineering Officer C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Mark A Wan director, 10 percent owner C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Three Arch Associates Iii Lp 10 percent owner C/O THREE ARCH PARTNERS, 3200 ALPINE ROAD, PORTOLA VALLEY CA 94028
Wilfred E Jaeger 10 percent owner C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Three Arch Partners Iii Lp 10 percent owner
Three Arch Partners Iv Lp 10 percent owner
Three Arch Associates Iv Lp 10 percent owner 3200 ALPINE ROAD, PORTOLA VALLEY CA 94028

Talphera (Talphera) Headlines

From GuruFocus